To date, PD-1/PD-L1 antibodies have been approved for treatment of several cancers including melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC) and bladder cancer—and the list is rapidly expanding [2]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.